AT1 Receptor Modulator Attenuates the Hypercholesterolemia–Induced Impairment of the Myocardial Ischemic Post-Conditioning Benefits

Yun-Wei Li, MD, Yan-Ming Li, MD, Yan Hon, MD, Qi-Lin Wan, MD, Rui-Li He, MD, Zhi-Zhong Wang, MD, and Cui-Hua Zhao, MD

Department of Cardiology, Henan University Huaihe Hospital, Henan, China

Background and Objectives: Ischemic post-conditioning (PostC) has been demonstrated as a novel strategy to harness nature’s protection against myocardial ischemia-reperfusion (I/R). Hypercholesterolemia (HC) has been reported to block the effect of PostC on the heart. Angiotensin II type-1 (AT1) modulators have shown benefits in myocardial ischemia. The present study investigates the effect of a novel inhibitor of AT1, azilsartan in PostC of the heart of normocholesterolemic (NC) and HC rats.

Materials and Methods: HC was induced by the administration of high-fat diet to the animals for eight weeks. Isolated Langendorff’s perfused NC and HC rat hearts were exposed to global ischemia for 30 min and reperfusion for 120 min. I/R-injury had been assessed by cardiac hemodynamic parameters, myocardial infarct size, release of tumor necrosis factor-alpha troponin I, lactate dehydrogenase, creatine kinase, nitrite in coronary effluent, thiobarbituric acid reactive species, a reduced form of glutathione, superoxide anion, and left ventricle collagen content in normal and HC rat hearts.

Results: Azilsartan post-treatment and six episodes of PostC (10 sec each) afforded cardioprotection against I/R-injury in normal rat hearts. PostC protection against I/R-injury was abolished in HC rat hearts. Azilsartan prevented the HC-mediated impairment of the beneficial effects of PostC in I/R-induced myocardial injury, which was inhibited by L-N5-(1-iminoethyl)ornithinehydrochloride, a potent inhibitor of endothelial nitric oxide synthase (eNOS).

Conclusion: Azilsartan treatment has attenuated the HC-induced impairment of beneficial effects of PostC in I/R-injury of rat hearts, by specifically modulating eNOS. Azilsartan may be explored further in I/R-myocardial injury, both in NC and HC conditions, with or without PostC. (Korean Circ J 2017;47(2):182–192)

KEY WORDS: AT1 receptor blocker; Ischemia-reperfusion injury; Azilsartan; myocardial infarction.

Introduction

Cardiac ischemic post-conditioning (PostC) is the technique wherein alternating cycles of sub-lethal myocardial ischemia and reperfusion are applied after a sustained insult. It is a cardioprotective strategy that can reduce reperfusion injury. Infarct size reduction and improvements in left ventricular ejection fraction have been demonstrated with mechanical or pharmacological postC after spontaneous acute myocardial infarction. Various pathways have been reported during ischemic postC such as reperfusion injury salvage kinase pathways (p44/42-ERK1/2, PI3k/AKT) as well as survival activating factor enhancement pathways (TNF-α, JAK/STAT). Hypercholesterolemia (HC) has been reported to abrogate the beneficial effects of postC in ischemia-reperfusion (I/R)-induced myocardial injury 4. It has been reported that HC abolishes the benefits of postC by alterations in cytochrome c, Akt, ERK1/2, caspase 9, caspase 3, nitric oxide synthase, endothelial nitric oxide synthase (eNOS), mitochondrial adenosine triphosphate (ATP)-dependent K+ channel, Bcl-2, Bax and PI3K/Akt/eNOS pathways. HC activates the renin-angiotensin system, increases angiotensin
II type 1 (AT1) receptor density and functional responsiveness of AT1 receptors. The angiotensin II type 1 receptor antagonist protects the heart against acute I/R injury. Furthermore, AT1 blockers have been reported to provide anti-inflammatory, anti-oxidative, cardio-protective, anti-hypertensive and beneficial effects in I/R myocardial injury.

Azilsartan is a new AT1 blocker that has been recently launched; nothing much is known about its utility in I/R myocardial injury, ischemic PostC of the heart and HC. The present study has been designed to investigate for the first time, the utility of a novel AT1 blocker, azilsartan in I/R injury and ischemic PostC of the heart of normal and hypercholesterolemic rats.

Materials and Methods

Animals
Male Wistar rats (weight 250 to 300 g) were obtained from Henan University Animal Public Service Centre (Henan, China). All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Research Review and Ethics board of Henan University Huaihe Hospital, Henan, China (Ref no. 20131110, dated 10 Nov, 2013). All the animals were housed at a temperature of 23°C, 60% humidity, and 12 h light/dark cycles. Water and food were freely available to the animals.

Drugs and chemicals
All the chemicals and reagents were of AR grade and prepared freshly before use.

Induction of HC in rats
Male Wistar rats (250-300 g) were employed in the present study. Experimental HC was induced in the animals by changing their diet with that of a high-fat diet for 8 weeks. The establishment of hyperlipidemia was confirmed by serum lipid profiling of the animals.

Isolated rat heart preparation
The rats were anesthetized with pentobarbital sodium (100 mg/kg intraperitoneally). The heart was immediately isolated and mounted on a Langendorff apparatus. A circulating water jacket was provided to surround the heart for temperature maintenance at 37°C. The preparation was perfused with Krebs Henseleit solution, pH 7.4, maintained at 37°C, and bubbled with 95% O2 and 5% CO2. The perfusion pressure was maintained at 80 mm of Hg for the maintenance of a coronary flow rate at around 7 mL/min. For induction of global ischemia, the inflow of Krebs Henseleit solution was blocked for 30 min, and then reperfusion for 120 min was re-established by allowing the inflow of Krebs Henseleit solution.

Left ventricular hemodynamic parameters were measured via a latex balloon inserted in the left ventricle. The balloon catheter was linked to a pressure transducer connected to the physiological signal acquisition system (PowerLab, AD Instruments, Shanghai, China) to monitor the contractile function. To induce the PostC we have utilized six cycles of 10 sec ischemias and 10 sec reperfusions, after the 30 min ischemia and before the 120 min reperfusion. This is an acceptable and widely used protocol for induction of PostC during ischemia and reperfusion injury of the isolated heart.

Experimental protocol
In the present study, a total of eleven groups were employed (n=12) as per the experimental protocol (Fig. 1). All the isolated Langendorff-perfused rat hearts were first allowed to stabilize with the help of a perfused Krebs Henseleit solution for 10 min.

Group I-sham control-normocholesterolemic (NC): The isolated rat heart was perfused with the Krebs Henseleit solution for 200 min.

Group II-I/R-NC: The isolated rat heart was exposed to global ischemia for 30 min, followed by reperfusion for 120 min with a Krebs Henseleit solution.

Group III-ischemic-post-conditioned-NC: The isolated rat heart was exposed to 30 min of global ischemia, followed by six cycles of 10 sec global ischemias and 10 sec reperfusions, to establish ischemic PostC in the heart. After that, the heart was reperfused for 120 min with a Krebs Henseleit solution.

Group IV-I/R-azilsartan post treatment-NC: The isolated rat heart was exposed to global ischemia for 30 min, followed by reperfusion for 120 min with an azilsartan (5 mM) solution. The concentration of azilsartan (5 mM) was selected on the basis of preliminary studies and previously published reports.

Group V-I/R-azilsartan post treatment: The isolated rat heart was exposed to 30 min of global ischemia followed by six cycles of 10 sec global ischemias and 10 sec reperfusions, to establish PostC in the heart. After that the heart was reperfused for 120 min with an azilsartan (5 mM) solution.

Group VI-sham control-HC: The heart was isolated from hypercholesterolemic and the remainder of the procedure was the same as that of group I.

Group VII-I/R-HC: The heart was isolated from hypercholesterolemic rat and the remainder of the procedure was the same as that of group II.

Group VIII-ischemic post-conditioned-HC: The heart was isolated from hypercholesterolemic rat and the remainder of the procedure was the same as that of group III.

Group IX-I/R-azilsartan post treatment-HC: The heart was isolated from hypercholesterolemic rat after a 120 min reperfusion period with azilsartan (5 mM) solution.

Group X-Sham control-HC: The heart was isolated from normocholesterolemic rat and the remainder of the procedure was the same as that of group I.

Group XI-I/R-azilsartan post treatment-HC: The heart was isolated from normocholesterolemic rat after a 120 min reperfusion period with azilsartan (5 mM) solution.
from hypercholesterolemic rat and the remainder of the procedure was the same as that of group IV. 

**Group X— ischemic post-conditioned—azilsartan post treatment—HC:** The heart was isolated from hypercholesterolemic rat and the remainder of the procedure was the same as that of group V.

**Group XI— ischemic post-conditioned—L-N5-(1-Iminobutyl)ornithine (L-NIO) hydrochloric acid azilsartan post treatment—HC:** The heart was isolated from hypercholesterolemic rat and perfused with a Krebs Henseleit solution for 10 min. After that, the heart was exposed to 30 min of global ischemia followed by six cycles of 10 sec global ischiemias and 10 sec reperfusions, to PostC in the heart. After that the heart was reperfused for 15 min with L-NIO hydrochloride (1 mM) followed by reperfusion for 105 min with an azilsartan (5 mM) solution.

**Estimation of lactate dehydrogenase, creatine kinase, tumor necrosis factor-alpha, troponin I and nitrite in coronary effluent**

To assess the myocardial injury, the release of lactate dehydrogenase (LDH) (0 and 30 min) and creatine kinase (CK-MB) (5 min) in the coronary effluent was estimated with the help of commercially available enzymatic kits (Bangjing, Shanghai, China). The concentrations of tumor necrosis factor-alpha (TNF-α) (1, 5, and 10 min), TnI (60 min) were measured by the sandwich ELISA technique (R&D system, Minneapolis, MN, USA) and quantified photometrically, at an absorbance of 450 nm. Furthermore, nitric oxide levels were measured (spectrophotometrically at 550 nm) as the nitrite concentration (0 and 15 min) uses Greiss reagent.13)

**Assessment of Infarct size and left ventricle collagen content**

The volume of the infarcted myocardium (% infarct size) uses triphenyl tetrazolium chloride14) and left ventricle collagen content15) using chloramines-T and Ehrlich’s reagent were measured as per the previously published reports.

**Assessment of oxidative stress**

The left ventricle was homogenized in an ice-cold phosphate buffer 0.05 M (pH 7.4) and the clear supernatant was utilized for the spectrophotometric measurement of thiobarbituric acid reactive substances (TBARS),16) superoxide anion (SA)17) and reduced form of glutathione (GSH)18) at 532 nm, 540 nm and 412 nm respectively, as per the previously published reports.

**Statistical analysis**

The results were expressed as a mean±standard deviation. The data was statistically analyzed using a one-way analysis of variance followed by Tukey’s multiple range test; p<0.05 was considered to be statistically significant.
Results

Effect of high-fat diet on serum lipids

The administration of a high fat diet has significantly increased the total cholesterol (260 mg/dL), triglycerides (210 mg/dL) and low-density lipoproteins (15 mg/dL) along with a significant reduction of high-density lipoproteins (30 mg/dL) as compared to the control animals (76 mg/dL; 63 mg/dL; 32 mg/dL; 45 mg/dL) on a normal chow diet.

Effect on hemodynamic parameters of heart

When compared to sham control, 30 min global ischemia and 120 min reperfusion in NC and HC animals have significantly enhanced left ventricular end-diastolic pressure along with a significant reduction in heart rate, left ventricular developed pressure, ±dP/dt max and coronary flow rate. I/R-injury induced impairment of hemodynamic parameters of hearts was attenuated by ischemic-PostC (six cycles of 10 sec ischemias and 10 sec reperfusions) and azilsartan post treatment in NC rats. HC has significantly abolished the beneficial effects of PostC on hemodynamic parameters. The perfusion of azilsartan to the heart of HC-ischemic post-conditioned animals has significantly normalized the beneficial effect of PostC on the hemodynamic parameters of heart, which were significantly inhibited by the L-NIO, a potent inhibitor of eNOS (Fig. 2).

Effect on the release of lactate dehydrogenase, creatine kinase and tumor necrosis factor-alpha

When compared to sham control, 30 min global ischemia and 120 min reperfusion in NC and HC animals have significantly enhanced LDH (at 0 min and 30 min of reperfusion), CK-MB (at 5 min of reperfusion) and TNF-α (at 1 min and 5 min of reperfusion). I/R-injury induced impairment in LDH, CK-MB, and TNF-α levels was attenuated by ischemic-PostC (six cycles of 10 sec ischemias and 10 sec reperfusions) and azilsartan post treatment in NC rats. HC has significantly abolished the beneficial effects of PostC on the heart. I/R-injury induced impairment of oxidative stress, which was significantly inhibited by the L-NIO, a potent inhibitor of eNOS (Fig. 3).

Effect on the release of nitrite and troponin I

When compared to sham control, a 30 min global ischemia and 120 min reperfusion in NC and HC animals have significantly reduced nitrite (at 0 min and 15 min of reperfusion), and troponin I (TnI) levels (at 60 min of reperfusion). I/R-injury induced impairment in nitrite and TnI levels, was attenuated by ischemic-PostC (six cycles of 10 sec ischemias and 10 sec reperfusions) and azilsartan post treatment in NC rats. HC has significantly abolished the beneficial effects of PostC on nitrite and TnI levels. The perfusion of azilsartan to the heart of HC-ischemic post-conditioned animals has significantly normalized the beneficial effect of PostC on the nitrite and TnI levels, which were significantly inhibited by the L-NIO, a potent inhibitor of eNOS (Fig. 4).

Effect on the % infarct size and left ventricle collagen content

When compared to sham control, a 30 min global ischemia and 120 min reperfusion in NC and HC animals have significantly enhanced the percentage of the infarction size and left ventricle collagen content of rat hearts. I/R-injury induced impairment in the percentage of the infarction size and left ventricle collagen content was attenuated by ischemic-PostC (six cycles of 10 sec ischemias and 10 sec reperfusions) and azilsartan post treatment in NC rats. HC has significantly abolished the beneficial effects of PostC on the percentage of the infarction size and left ventricle collagen content. The perfusion of azilsartan to the heart of HC-ischemic post-conditioned animals has significantly normalized the beneficial effect of PostC on the percentage of the infarction size and left ventricle collagen content, which were significantly inhibited by the L-NIO, a potent inhibitor of eNOS (Fig. 5).

Effect on the heart oxidative stress

When compared to sham control, a 30 min global ischemia and 120 min reperfusion in NC and HC animals have significantly enhanced the heart’s oxidative stress (noted as a significant increase in TBARS and SA along with significant reduction in GSH levels of the heart). I/R-injury enhanced oxidative stress, was attenuated by ischemic-post-conditioning (six cycles of 10 sec ischemias and 10 sec reperfusions) and azilsartan post treatment in NC rats. HC has significantly abolished the beneficial effects of PostC on oxidative stress. The perfusion of azilsartan to the heart of HC-ischemic PostC animals has significantly normalized the beneficial effect of PostC on oxidative stress, which was significantly inhibited by the L-NIO, a potent inhibitor of eNOS (Fig. 6).

Discussion

I/R induced injury of heart

In the present study, a 30 min ischemia and 120 min reperfusion significantly induced myocardial injury, when compared to sham control animals. I/R myocardial injury has been shown to have a direct correlation of infarct size with that of cardiac hemodynamic
Fig. 2. Effect of azilsartan perfusion on the hemodynamic parameters of an isolated heart in ischemia-reperfusion injury and ischemic-post conditioning of normal and hypercholesterolemic rats. Results are expressed as mean ± standard deviation. *p<0.05 vs. sham control group; †p<0.05 vs. I/R-NC group; ‡p<0.05 vs. sham control-HC group; §p<0.05 vs. I/R-HC group; ‡‡p<0.05 vs. AZ+PostC-I/R-HC group. BMP: beats per minute, NC: normocholesterolemic, I/R: ischemia-reperfusion, PostC: post-conditioning, AZ: azilsartan, HC: hypercholesterolemic, L-NIO: selective eNOS inhibitor, LVEDP: left ventricular end-diastolic pressure, LVPP: left ventricular protection period.
parameters, release of LDH, CK-MB, TnI and inflammatory markers like TNF-α, in the coronary effluent after an ischemic insult to the myocardium. LDH release was found to be maximum at 0 min, i.e. immediately after the reperfusion. On the other hand CK-MB and TNF-α release was found to be maximum at 5 min intervals.

High level of oxidative stress in I/R is evident by significantly higher levels of TBARS, and SA, along with significantly lower levels of GSH, was found in the heart exposed to I/R injury. TNF-α is a specific marker of inflammation and its higher levels in the coronary effluent signifies the high level of inflammation during I/R injury. Lower levels of nitrite are an index of decreased availability of NO which may result in cardiac damage.

Higher levels of collagen content in the left ventricle signify a possible cardiac death during I/R injury of the heart. All the above alterations have resulted in increased myocardial injury and death, which has resulted in increased infarct size and

**Fig. 3.** Effect of azilsartan perfusion on (A) LDH, (B) K-MB and (C) TNF-α in ischemia-reperfusion injury and ischemic-post conditioning of normal and hypercholesterolemic rats. Results are expressed as mean±standard deviation. *p<0.05 vs. sham control-NC group. **p<0.05 vs. I/R-NC group. ***p<0.05 vs. sham control-HC group. ****p<0.05 vs. I/R-HC group. *****p<0.05 vs. AZ+PostC-I/R-HC group. LDH: lactate dehydrogenase, CK-MB: creatine kinase, TNF-α: tumor necrosis factor-alpha, NC: normocholesterolemic; I/R: ischemia-reperfusion, NC: normocholesterolemic, PostC: post-conditioning, HC: hypercholesterolemic, AZ: azilsartan, L-NIO: selective eNOS inhibitor.
Fig. 4. Effect of azilsartan perfusion on (A) nitrite levels and (B) TnI in ischemia-reperfusion injury and ischemic-post conditioning of normal and hypercholesterolemic rats. Results are expressed as mean±standard deviation. a<0.05 vs. sham control-NC group. b<0.05 vs. I/R-NC group. c<0.05 vs. sham control–HC group. d<0.05 vs. I/R-HC group. e<0.05 vs. AZ+PostC-I/R–HC group. TnI: troponin-I, NC: normocholesterolemic, HC: hypercholesterolemic, AZ: azilsartan, I/R: ischemia-reperfusion, PostC: post-conditioning, L-NIO: selective eNOS inhibitor.

Fig. 5. Effect of azilsartan perfusion on (A) percent infarct size and (B) left ventricle collagen content in ischemia-reperfusion injury and ischemic-post conditioning of normal and hypercholesterolemic rats. Results are expressed as mean±standard deviation. a<0.05 vs. sham control-NC group. b<0.05 vs. I/R-NC group. c<0.05 vs. sham control-HC group. d<0.05 vs. I/R-HC group. e<0.05 vs. AZ+PostC-I/R–HC group. NC: normocholesterolemic, HC: hypercholesterolemic, AZ: azilsartan, I/R: ischemia-reperfusion, PostC: post-conditioning, L-NIO: selective eNOS inhibitor.
consequent reduction in the coronary flow rate during an I/R-induced myocardial injury. These findings are in accordance with the previously published reports.9)13)14)

**Beneficial effect of ischemic PostC in I/R-injury of heart**

Six cycles of 10 sec ischernias and 10 sec reperfusions have post-conditioned the normal rat heart against the myocardial injury during the I/R insult of a 30 min ischemia and 120 min reperfusion. PostC has markedly attenuated the I/R myocardial injury in normal rat hearts and the results are in parallel to previous studies.4)5) Cardiac ischemic post conditioning-the technique of applying alternating cycles of sub-lethal myocardial ischemia and reperfusion after a sustained insult-is one cardioprotective strategy that can reduce reperfusion injury. Infarct size reduction and improvements in left ventricular ejection fraction have been demonstrated with mechanical or pharmacological PostC, both after a spontaneous acute myocardial infarction, and associated with cardiac surgery.1) Badalzadeh et al.10) have reported that I/R injury may mitochondrial ATP-dependent potassium (mito-KATP) channels and nitric oxide system as the main players in the induction of a myocardial injury. In our study, the disturbance in the nitric oxide system is evident as there was a reduction of nitrite release in the coronary effluent after an ischemic insult. It has been suggested that during an I/R injury of the heart, activation of IkB and NFkB occur.20) These are the important modulators of inflammation; high levels of inflammations are evident from the increase in the release of TNF-α in this study.

**HC abolished benefits of ischemic–PostC, in I/R injury of heart**

Administration of a high-fat diet rich in cholesterol to the rats for 8 weeks had markedly enhanced the total serum cholesterol, triglycerides and low-density lipoproteins along with the reduction of beneficial lipids, and high-density lipoproteins. Thus, a high-fat diet has successfully established HC as well as hyperlipidemia in the rats. When the hearts of hypercholesterolemic rats were exposed to the PostC, PostC achieved very limited protection in I/R myocardial injury. HC has abolished PostC induced correction of hemodynamic parameters, reduction in the infarct size, release of LDH, CK-MB, TNF-α, TnI, left ventricle collagen content, TBARS, SA along with the increase of coronary flow rate, nitrite release, and GSH levels. This suggests that HC has significantly abolished all the benefits of PostC in I/R injury of hypercholesterolemic rats heart, which is in parallel to previous studies.4)6) It has been suggested that HC may induce excessive apoptosis by down-regulating Bcl-2 and upregulating Bax, cytochrome c, caspase 9 and caspase 3.
Benefits of AT1 blocker in I/R injury and ischemic-post-conditioning in normal as well as hypercholesterolemic heart: role of eNOS

The perfusion of the novel AT1 receptor inhibitor, azilsartan post treatment has significantly protected the I/R induced injury of heart in normocholesterolemic animals, in a similar manner as that of PostC mediated protection in I/R injury of normal animals. Furthermore, perfusion of azilsartan in hypercholesterolemic-ischemic post-conditioned animals has significantly reversed the HC induced inhibition of the beneficial effects of PostC. In I/R myocardial injury and hypercholesterolemic-ischemic post-conditioned animals, perfusion of azilsartan has significantly corrected the hemodynamic parameters of the heart, reduced the release of LDH, CK-MB, TNF-α, TnI nitrite in coronary effluent, oxidative stress, left ventricle collagen content, infarct size along with significant correction of coronary flow rate. Previously various in-vitro doses of azilsartan have been utilized such as 1 mM and 0.005% (-3 mM). In our preliminary studies, we have first utilized and 5 mM/L doses of azilsartan. The significant protection was observed with 5 mM/L doses (data not shown), which was then selected for the protocol of the present study.

To understand the exact mechanism behind the beneficial effects of azilsartan (a novel AT1 receptor antagonist), on PostC in hypercholesterolemic rat heart, we have employed the L-NIO, which is a potent inhibitor of eNOS. The beneficial effects of azilsartan perfusion on PostC in hypercholesterolemic rat heart was significantly inhibited by the perfusion of L-NIO which suggests that azilsartan has provided beneficial effects on PostC in hypercholesterolemic rat heart by specific modulation of eNOS.

Azilsartan is an angiotensin receptor blocker which is recently approved for treating patients with hypertension, introduced in the year 2011, which exerts its benefits predominantly through AT1 receptors. It has been reported that azilsartan provided kidney and heart protective effects due to its ability to lower blood pressure and improve endothelial functions. Iwanami and colleagues have reported that the hypotensive and anti-hypertrophic effects of azilsartan may involve activation of the ACE2/Ang-(1-7)/Mas axis with AT1 receptor blockade. The azilsartan has been shown to exert favorable biological effects on the hearts during left ventricular pressure overload in obese insulin-resistant conditions. In vitro studies showed that azilsartan medoxomil was hydrolyzed rapidly to azilsartan in plasma, hepatic S9 fractions, and intestinal S9 fractions from all species tested. In human hepatic microsomes, azilsartan was further decarboxylated to the pharmacologically inactive metabolite M-I by the cytochrome P450 enzyme (CYP) 2C8, or was O-dealkylated to the inactive metabolite M-II by CYP2C9. The half maximal inhibitory concentration (IC50) values for azilsartan medoxomil for the in vitro inhibition of human hepatic CYP isoforms, CYP2C8, CYP2C9, CYP3A4, CYP2B6, CYP1A2, and CYP2C19 ranged from 3.5 to 66 µmol/L.

Not much is known about the utility of azilsartan in I/R-induced myocardial injuries, PostC, and HC. Asiltsartan has been reported to provide protection against oxidative stress and inflammation. Furthermore, it has also been found that azilsartan improves lipid profiles, heart function, and endothelial function as well. It has been suggested that azilsartan decreases TNF-α expression better than candesartan cilexetil. Non-hypertensive doses of azilsartan have been reported to cause cardiomyocyte remodeling, infarct size and fibrotic changes after induction of myocardial infarction. It has been reported earlier that, eNOS dysfunction is one of the important pathways during myocardial I/R-injury. Wu et al. have reported that PostC provides benefits in I/R-injury of heart by upregulation of eNOS. HC has been reported to abolish the beneficial effects of PostC during I/R-injury of heart by impairing eNOS function. AT1 blockers have been reported to enhance eNOS expression. Matsumoto et al. have reported that azilsartan treatment corrects the phosphorylation of eNOS. Thus, azilsartan, a novel AT1 blocker may have provided its benefits due to its anti-oxidative stress, cardioprotective, anti-inflammatory, and nitric oxide-releasing effects via modulation of eNOS.

Conclusions

The results of this study suggests following aspects of azilsartan, which are unique to this study: 1) azilsartan significantly provides protection in I/R-induced myocardial injuries in normocholesterolemic rats, similar to the benefits provided by PostC in I/R-induced myocardial injuries in normocholesterolemic rats; 2) azilsartan has also re-established the beneficial effects of PostC in I/R myocardial...
injuries, abolished by HC; 3) azilsartan has also provided its beneficial effects through specific modulation of eNOS. Further, research on azilsartan is warranted to unearth the various other mechanisms involved in the beneficial effects in I/R injury and PostC of the heart.

Acknowledgements

The authors are thankful to Department of Cardiology, Henan University Huaihe Hospital, Henan, China for providing us the research facilities for conducting this research.

References

1. Jivraj N, Liew F, Marber M. Ischaemic postconditioning: cardiac protection after the event. *Anaesthesia* 2015;70:598-612.
2. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. *Cardiovasc Res* 2004;61:448-60.
3. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? *J Mol Cell Cardiol* 2009;47:32-40.
4. Wu N, Zhang X, Jia P, Jia D. Hypercholesterolemia abrogates the protective effect of ischemic postconditioning by induction of apoptosis and impairment of activation of reperfusion injury salvage kinase pathway. *Biochem Biophys Res Commun* 2015;458:148-53.
5. Wu N, Li W, Shu W, Lv Y, Jia D. Inhibition of Rho-kinase by fasudil restores the cardioprotection of ischemic postconditioning in hypercholesterolemic rat heart. *Mol Med Rep* 2014;10:2517-24.
6. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension–lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. *Am J Med Sci* 2002;323:17-24.
7. Li KY, Zhang YJ. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in isolated ischaemia and reperfused rat hearts. *Acta Cardiol* 2015;70:67-72.
8. Skorska A, von Haehling S, Ludwig M, et al. The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function. *J Cell Mol Med* 2015;19:1975-85.
9. Kansal SK, Jyoti U, Sharma S, Kaura A, Deshmukh R, Goyal S. Effect of zinc supplements in the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart. *Naunyn Schmiedebergs Arch Pharmacol* 2015;388:635-41.
10. Badalzadeh R, Yousefi B, Majidinia M, Ebrahimi H. Anti-arrhythmic effect of diosgenin in reperfusion-induced myocardial injury in a rat model: activation of nitric oxide system and mitochondrial KATP channel. *J Physiol Sci* 2014;64:393-400.
11. Miura S, Matsuo Y, Nakayama A, Tomita S, Suematsu Y, Saku K. Ability of the new AT1 receptor blocker azilsartan to block angiotensin II–induced AT1 receptor activation after wash-out. *J Renin Angiotensin Aldosterone Syst* 2014;15:7-12.
12. Matsumoto S, Shimabukuro M, Fukuda D, et al. Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice. *Cardiovasc Diabetol* 2014;13:30.
13. Parikh V, Singh M. Possible role of cardiac mast cell degranulation and preservation of nitric oxide release in isolated rat heart subjected to ischemic preconditioning. *Mol Cell Biochem* 1999;199:1-6.
14. Sato T, Sato H, Oguchi T, et al. Insulin preconditioning elevates p-Akt and cardiac contractility after reperfusion in the isolated ischemic rat heart. *Biomed Res Int* 2014;2014:536510.
15. Jamal IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. *Anal Biochem* 1981;112:70-5.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979;95:351-8.
17. Wang HD, Pagano PJ, Du Y, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. *Circ Res* 1998;82:810-8.
18. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med* 1963;61:882-8.
19. Bopassa JC, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ozive M. PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. *Cardiovas Res* 2006;69:178-85.
20. Xu T, Tang H, Zhang B, et al. Exercise preconditioning attenuates pressure overload-induced pathological cardiac hypertrophy. *Int J Clin Exp Pathol* 2015;8:530-40.
21. Carroll MA, Kang Y, Chander PN, Stier CT Jr. Azilsartan is associated with increased circulating angiotensin-(1–7) levels and reduced renovascular 20-HETE levels. *Am J Hypertens* 2015;28:664-71.
22. Hye Khan MA, Neckář J, Cummens B, Wahl DM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. *Cardiovasc Drugs Ther* 2014;28:313-22.
23. Iwanami J, Mogi M, Tsukuda K, et al. Direct angiotensin II receptor stimulation by compound 21 prevents vascular dementia. *J Am Soc Hypertens* 2015;9:250-6.
24. Tarikuz Zaman AK, McLean DL, Sobel BE. The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload. *J Cardiovasc Pharmacol* 2013;62:381-7.
25. Summary Basis of Decision-SBD for *EDARBI* [Internet]. Canada: Azilsartan medoxomil, Bureau of Cardiology, Allergy and Neurological Sciences, Health Canada; 2012 Jun [cited 2016 Jan].
Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_edarbi_145305-eng.php.

26. Sgarra L, Leo V, Addabbo F, et al. Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors. PLoS One 2014;9:e88542.

27. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007;20:579-86.

28. Nakamura Y, Suzuki S, Saitoh S, Takeishi Y. New angiotensin II type 1 receptor blocker, azilsartan, attenuates cardiac remodeling after myocardial infarction. Biol Pharm Bull 2013;36:1326-31.

29. Yang JT, Qian LB, Zhang FJ, et al. Cardioprotective effects of luteolin on ischemia/reperfusion injury in diabetic rats are modulated by eNOS and the mitochondrial permeability transition pathway. J Cardiovasc Pharmacol 2015;65:349-56.

30. Huisamen B, Pêrel SJ, Friedrich SO, Salie R, Strijdom H, Lochner A. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem 2011;349:21-31.